NCT00002358

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 2 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.

Detailed description

Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.

Conditions

• HIV Infections
• Chickenpox

Interventions

Type	Name	Description
DRUG	Sorivudine

Timeline

• First posted: 2001-08-31
• Last updated: 2007-10-02

Locations

1 site across 1 country: United States